Department of Urology, NHO Shikoku Cancer Center, 160 Minamiumemoto, Matsuyama, Ehime, 791-0280, Japan.
Division of Cancer Prevention and Epidemiology, Center for Cancer Research, NHO Shikoku Cancer Center, Matsuyama, Japan.
BMC Urol. 2024 Nov 9;24(1):248. doi: 10.1186/s12894-024-01646-x.
We previously conducted a retrospective Japanese cohort study of patients who underwent radical prostatectomy (RP) between January 2010 and December 2020 in Ehime Prefecture. This study revealed an increase in the number of RP, but other treatment trends remained unclear. In the current study, we examined prostate cancer treatment in Ehime Prefecture using the hospital-based cancer registry of all designated cancer care hospitals and community cancer care hospitals belonging to the Council of Ehime Cancer Care Hospitals.
Trends of prostate cancer were compared by year according to stage and treatment using data from the hospital-based cancer registry between 2011 and 2020.
The number of patients with stage 1 disease increased over time, but the proportion of patients with stage 1 disease among all patients decreased from 65.2% in 2012 to 56.9% in 2020. The number of patients with stage 2 disease also increased, but the proportion of such patients among all patients remained constant. Meanwhile, the proportions of patients with stage 3 or 4 disease increased significantly over time, while that of patients undergoing RP increased from 29.2% in 2011 to 45.7% in 2020 (P < 0.001). The proportion of patients receiving radiotherapy (RT) decreased from 25.8% in 2011 to 17.2% in 2020. The use of hormone therapy (HT) remained unchanged, and the proportion of patients undergoing observation fell from 11.0% in 2011 to 7.0% in 2020. A higher proportion of patients with stage 3 cancer received HT, and RT was more frequently used in stage 3 cancer than in stage 1-2 cancer. The use of HT increased with age.
The data highlighted differences in prostate cancer stages and treatment over time. This information could be shared with both urologists and radiologists to improve treatment.
我们之前进行了一项回顾性的日本队列研究，纳入了 2010 年 1 月至 2020 年 12 月期间在爱媛县接受根治性前列腺切除术（RP）的患者。该研究显示 RP 数量有所增加，但其他治疗趋势仍不清楚。在本研究中，我们使用所有指定癌症护理医院和爱媛癌症护理医院协会所属社区癌症护理医院的基于医院的癌症登记处的数据，检查了爱媛县的前列腺癌治疗情况。
根据 2011 年至 2020 年基于医院的癌症登记处的数据，按分期和治疗方法逐年比较前列腺癌的趋势。
1 期疾病患者的数量随时间增加，但 1 期疾病患者在所有患者中的比例从 2012 年的 65.2%下降到 2020 年的 56.9%。2 期疾病患者的数量也有所增加，但此类患者在所有患者中的比例保持不变。与此同时，3 期或 4 期疾病患者的比例随时间显著增加，而接受 RP 的患者比例从 2011 年的 29.2%增加到 2020 年的 45.7%（P<0.001）。接受放疗（RT）的患者比例从 2011 年的 25.8%下降到 2020 年的 17.2%。激素治疗（HT）的使用保持不变，观察治疗的患者比例从 2011 年的 11.0%下降到 2020 年的 7.0%。更多 3 期癌症患者接受 HT，RT 在 3 期癌症中比在 1-2 期癌症中更常用。HT 的使用随年龄增加而增加。
这些数据强调了前列腺癌分期和治疗随时间的变化。这些信息可以与泌尿科医生和放射科医生分享，以改善治疗效果。
